Nevertheless, blockade of IL-6, which is a key pathway in immune defence, could raise the risk of serious infections in T1D patients and hence targeting the therapy to a specific cell type could offer advantages in therapy. This evidence concerns the gene IL6 and type 1 diabetes mellitus.